Free Trial
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel
NASDAQ:ORMP

Oramed Pharmaceuticals Q3 2026 Earnings Date & Estimates

Oramed Pharmaceuticals logo
$4.07 -0.11 (-2.63%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$4.08 +0.01 (+0.25%)
As of 10/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Oramed Pharmaceuticals is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. The conference call is scheduled for November 6, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Oramed Pharmaceuticals in Q3 2026

Oramed Pharmaceuticals is expected to post earnings of $0.43 per share. Oramed Pharmaceuticals last reported on August 10, 2026, posting -$0.09 per share and missing the $0.43 consensus estimate. Oramed Pharmaceuticals has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.43

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.09 (Missed by -$0.52)
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Oramed Pharmaceuticals Q3 2026 Earnings FAQ

Oramed Pharmaceuticals (NASDAQ:ORMP) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Oramed Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Oramed Pharmaceuticals to post earnings of $0.43 per share for Q3 2026.

Oramed Pharmaceuticals Earnings Headlines

Financial Contrast: Recursion Pharmaceuticals (NASDAQ:RXRX) vs. Oramed Pharmaceuticals (NASDAQ:ORMP)
October 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31098806
Oramed Pharmaceuticals consensus price target increased 12.00% to $7.14
September 15, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/oramed-pharmaceuticals-consensus-price-target-increased-12-00-to-7-14/ar-AA2chzvw
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
 |  Chaikin Analytics (Ad)
Oramed: Q2 Earnings Snapshot
August 11, 2026  |  chron.comhttps://www.chron.com/business/article/oramed-q2-earnings-snapshot-22382586.php
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
June 25, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/oramed-releases-letter-to-shareholders-highlighting-russell-20003000-index-inclusion-scilex-loan-repayment-strategic-portfolio-appreciation-and-a-strengthened-balance-sheet-302810903.html
ORMP: View inclusion in Russell indexes as positive that could raise awareness in investment community
June 18, 2026  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/ormp-view-inclusion-in-russell-indexes-as-positive-that-could-raise-awareness-in-investment-community/ar-AA25Z9Hc
See More Oramed Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oramed Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oramed Pharmaceuticals and other key companies, straight to your email.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals (NASDAQ:ORMP) is a biopharmaceutical company focused on developing oral delivery technologies for biologic drugs, including proteins and peptides that are traditionally administered by injection. Its technology is designed to protect these therapies as they pass through the gastrointestinal tract and facilitate absorption into the bloodstream.

The company’s lead programs have included ORMD-0801, an oral insulin candidate developed for the treatment of diabetes, and oral formulations of other peptide-based therapies. Oramed has evaluated its candidates in clinical studies involving patients with diabetes and has also pursued partnerships and licensing opportunities to advance its oral drug-delivery platform.

Founded in 2006, Oramed is headquartered in Jerusalem, Israel, and has maintained corporate operations in the United States. Nadav Kidron has served as the company’s chief executive officer, while Professor Miriam Kidron, one of the company’s founders, has been associated with its scientific leadership. The company’s shares trade on the Nasdaq Capital Market under the symbol ORMP.

View Oramed Pharmaceuticals Profile
Earnings Tools